Research

Research

KU Eye physicians performing cutting-edge, basic, clinical and applied research in ophthalmology and vision science

 

Faculty as Principle Investigator

Dry Eye Assessment and Management (DREAM) Study  (click here for more information and enrollment details!)

Principle Investigator: John Sutphin, MD

Sub-investigator: Miranda Bishara, MD


INTACS Prescription Inserts For Keratoconus--Humanitarian Use Device

Principle Investigator: John Sutphin, MD


Faculty as Sub-Investigator

AGS67E (AGENSYS) - A Phase 1 Study Evaluating Safety, Tolerability and Pharmacokinetics of Escalating Doses of AGS7E given as Monotherapy in Subjects with Refractory or Relapses Lymphoid Malignancies.

Principle Investigator: Ruben Reyes, MD, Hematology/Oncology

Suib-Investigators: Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


ASG-22CE-13-2 (AGENSYS) A Study of Escalating Doses of ASG-22CE as Monotherapy in Subjects with Metastatic Urothelial Cancer

Principle Investigator: Peter Van Veldhuizen, MD, Hematology/Oncology

Sub-Investigators: Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


ASP2215-CL-0103 (APGD) - A Phase 1 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

Principle Investigator: Tara Lin, MD, Hematology/Oncology

Sub-Investigators: Paul Munden, MD and W. Abraham White, MD


Wet LabCBYL719XUS06T - PhaseI/II Study of BYL719 and Nab-Paclitaxel in Subjects with Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Principle Investigator: Priyanka Sharma, MD, Hematology/Oncology

Sub-Investigators: Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


CICL670AUS47 - A 2-year, Multi-Center, Phase II, Open-Label, Fixed-Dose, Randomized Comparative Trial of Azacitidine, with or without Deferasirox in Patients with Higher Risk Myelodysplastic Syndromes

Principle Investigator: Abdulraheem Yacoub, MD, Hematology/Oncology

Sub-Investigators: Miranda Bishara, MD; Paul Munden, MD; and W. Abraham White, MD


GS-US-352-1214 - A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Avaialble Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-Polycythemiai Vera Myelofibrosis or Post-Essential Thrombocytopenic Myelofibrosis who were Treated with Ruxolitinib

Principle Investigator: Abdulraheem Yacoub, MD, Hematology/Oncology

Sub-Investigators: Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


ISIS304801 - The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia

Principle Investigator: Patrick Moriarty, MD, Clinical Pharmacology

Subj-Investigator: Paul Munden, MD


CD-IA-MEDI-551-1155 - A Double-Masked, Placebo-Controlled Study with Open Label Period to Evaluate MEDI-551 in NMO and NOSD

Principle Investigator: Sharon Lynch, MD, Multiple Sclerosis Clinic

Subj-Investigators: Paul Munden, MD; W. Abraham White, MD and Thomas Whittaker, MD


Novartis BA312 - CBAF312X2205 - A Multi-Center, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients with Polymyositis

Principle Investigator: Mazen Dimachkie, MD, Neuromuscular Clinic

Sub-Investigators: Comprehensive Ophthalmologists


Ajay Singh, MD reviewing test resultsS1310 (National Cancer Institute) - Randomized Phaze II Trial of Single Agent MEK Inhibitor Trametinib vs. 5-Fluoroacil or Capecitabine in Refractory Advanced Biliary Cancer

Principle Investigator: Joaquina Baranda, MD, Hematology/Oncology

Sub-Investigators: Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients with Relapsing Multiple Sclerosis - Not currently enrolling

Principle Investigator: Sharon Lynch, MD, Multiple Sclerosis Clinic

Sub-investigator: Thomas Whittaker, MD


Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis

Principle Investigator: Sharon Lynch, MD, Multiple Sclerosis Clinic

Sub-investigator: Thomas Whittaker, MD


A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 1.25 mg FTY720 Administered Orally Daily Versus Placebo in Patients with Primary Progressive Multiple Sclerosis

Principle Investigator: Sharon Lynch, MD, Multiple Sclerosis Clinic

Sub-investigator: Thomas Whittaker, MD; Miranda Bishara, MD; Dirck Dekeyser, OD


IMGN853-0401 (First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IMGN853 in adults with ovarian cancer and other FOLR1-positive solid tumors (IMGN-0401))

Principle Investigator: KUMC Cancer Center

Sub-Investigators:  Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


A randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with dermatomyositis

Principal Investigator:  Richard Barohn, MD, Neurology, Frontiers: The Heartland Institute for Clinical and Translational Research

Sub-investigators:  Comprehensive Ophthalmologists


A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis

Principle Investigator: Sharon Lynch, MD, Multiple Sclerosis Clinic

Sub-investigator: OCT exam by technicnians

Last modified: Jun 04, 2015
ID=x8292